Benzinga | Aug 10, 2020 04:03PM EDT

Halozyme Therapeutics Q2 EPS $0.19 Misses $0.25 Estimate, Sales $55.20M Miss $66.68M Estimate

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $0.19 per share which missed the analyst consensus estimate of $0.25 by 24 percent. This is a 290 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $55.20 million which missed the analyst consensus estimate of $66.68 million by 17.22 percent. This is a 41.00 percent increase over sales of $39.15 million the same period last year.